World Bank Pharmaceuticals
Pharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and th...
| Main Authors: | , , |
|---|---|
| Format: | Working Paper |
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2013
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals http://hdl.handle.net/10986/13734 |
| id |
okr-10986-13734 |
|---|---|
| recordtype |
oai_dc |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English en_US |
| topic |
APPRAISAL REPORTS BIDDING CAPACITY BUILDING CASE STUDY CONTRACEPTIVES CORRUPTION COUNTERFEIT DRUGS DECISION MAKING DELIVERY SYSTEMS DEVELOPED COUNTRIES DEVELOPING COUNTRIES DEVELOPING COUNTRY DEVELOPMENT GOALS DEVELOPMENT INDICATORS DEVELOPMENT NETWORK DEVELOPMENT PARTNERS DEVELOPMENT STUDIES DISTRIBUTION SYSTEMS DRUG FINANCING DRUG INDUSTRY DRUG POLICY DRUG SELECTION ECONOMIC GROWTH ECONOMICS ESSENTIAL DRUGS FINANCIAL SUPPORT FORMAL POLICY HEALTH CARE HEALTH CARE PROVISION HEALTH EXPENDITURES HEALTH NEEDS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH WORKERS HEPATITIS B HOUSEHOLD INCOME HUMAN CAPITAL HUMAN DEVELOPMENT IMPORTED DRUGS IMPROVED HEALTH INCOME COUNTRIES INDIVIDUAL COUNTRIES INSTITUTIONAL ANALYSIS INTERNATIONAL MARKET INTERVENTION LOW-INCOME COUNTRIES MALARIA MANAGEMENT MANAGEMENT CAPACITY MANAGERS MARKET FAILURES MARKET INCENTIVES MEDICAL SUPPLIES MEDICINE MEDICINES MOTIVATION NATIONAL DRUG POLICIES NATIONAL DRUG POLICY NATIONAL ESSENTIAL DRUG LISTS NATIONAL ESSENTIAL DRUGS LISTS NATIONAL POLICIES NDP NON- GOVERNMENTAL ORGANIZATIONS NUTRITION PARTNER INSTITUTIONS PARTNERSHIP PATENTS PATIENTS PHARMACEUTICAL COMPANIES PHARMACEUTICAL FINANCING PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTION PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATORY AGENCIES PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL SYSTEMS PHARMACEUTICAL WAREHOUSING PHARMACEUTICALS PHARMACIES POLICY ANALYSIS POLICY DIALOGUE POLICY DOCUMENT POLICY FRAMEWORK POLICY IMPLICATIONS POLICY PROCESS PRICE COMPARISONS PRIMARY HEALTH CARE PRIVATE SECTOR PRIVATE SECTORS PROJECT IMPLEMENTATION PUBLIC AGENCIES PUBLIC HEALTH PUBLIC POLICIES PUBLIC POLICY PUBLIC SECTOR PURCHASING QUALITY ASSURANCE QUALITY CONTROL RATIONAL USE OF DRUGS SAFETY SCHOOLS SOCIAL MARKETING STRUCTURAL ADJUSTMENT TASK TEAM LEADERS TECHNICAL ASSISTANCE THERAPIES VACCINES WIDESPREAD CORRUPTION WORKERS PHARMACEUTICALS BURDEN OF DISEASE HEALTH CARE SYSTEMS MULTILATERAL ORGANIZATIONS HEALTH CARE HEALTH CARE FINANCE HEALTH CARE FINANCING HEALTH SYSTEMS DEVELOPMENT & REFORM |
| spellingShingle |
APPRAISAL REPORTS BIDDING CAPACITY BUILDING CASE STUDY CONTRACEPTIVES CORRUPTION COUNTERFEIT DRUGS DECISION MAKING DELIVERY SYSTEMS DEVELOPED COUNTRIES DEVELOPING COUNTRIES DEVELOPING COUNTRY DEVELOPMENT GOALS DEVELOPMENT INDICATORS DEVELOPMENT NETWORK DEVELOPMENT PARTNERS DEVELOPMENT STUDIES DISTRIBUTION SYSTEMS DRUG FINANCING DRUG INDUSTRY DRUG POLICY DRUG SELECTION ECONOMIC GROWTH ECONOMICS ESSENTIAL DRUGS FINANCIAL SUPPORT FORMAL POLICY HEALTH CARE HEALTH CARE PROVISION HEALTH EXPENDITURES HEALTH NEEDS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH WORKERS HEPATITIS B HOUSEHOLD INCOME HUMAN CAPITAL HUMAN DEVELOPMENT IMPORTED DRUGS IMPROVED HEALTH INCOME COUNTRIES INDIVIDUAL COUNTRIES INSTITUTIONAL ANALYSIS INTERNATIONAL MARKET INTERVENTION LOW-INCOME COUNTRIES MALARIA MANAGEMENT MANAGEMENT CAPACITY MANAGERS MARKET FAILURES MARKET INCENTIVES MEDICAL SUPPLIES MEDICINE MEDICINES MOTIVATION NATIONAL DRUG POLICIES NATIONAL DRUG POLICY NATIONAL ESSENTIAL DRUG LISTS NATIONAL ESSENTIAL DRUGS LISTS NATIONAL POLICIES NDP NON- GOVERNMENTAL ORGANIZATIONS NUTRITION PARTNER INSTITUTIONS PARTNERSHIP PATENTS PATIENTS PHARMACEUTICAL COMPANIES PHARMACEUTICAL FINANCING PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTION PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATORY AGENCIES PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL SYSTEMS PHARMACEUTICAL WAREHOUSING PHARMACEUTICALS PHARMACIES POLICY ANALYSIS POLICY DIALOGUE POLICY DOCUMENT POLICY FRAMEWORK POLICY IMPLICATIONS POLICY PROCESS PRICE COMPARISONS PRIMARY HEALTH CARE PRIVATE SECTOR PRIVATE SECTORS PROJECT IMPLEMENTATION PUBLIC AGENCIES PUBLIC HEALTH PUBLIC POLICIES PUBLIC POLICY PUBLIC SECTOR PURCHASING QUALITY ASSURANCE QUALITY CONTROL RATIONAL USE OF DRUGS SAFETY SCHOOLS SOCIAL MARKETING STRUCTURAL ADJUSTMENT TASK TEAM LEADERS TECHNICAL ASSISTANCE THERAPIES VACCINES WIDESPREAD CORRUPTION WORKERS PHARMACEUTICALS BURDEN OF DISEASE HEALTH CARE SYSTEMS MULTILATERAL ORGANIZATIONS HEALTH CARE HEALTH CARE FINANCE HEALTH CARE FINANCING HEALTH SYSTEMS DEVELOPMENT & REFORM Govindaraj, Ramesh Reich, Michael R. Cohen, Jillian C. World Bank Pharmaceuticals |
| relation |
HNP discussion paper series; |
| description |
Pharmaceuticals have a major impact on
health, on government and household spending, and on health
systems. Despite the fundamental role of pharmaceuticals,
there remains a profound gap between the benefit which
pharmaceuticals have to offer and the reality that for
millions of people -- particularly poor and disadvantaged
people -- medicines are unavailable, unaffordable, unsafe or
improperly used. This World Bank Pharmaceuticals Discussion
Paper provides a pragmatic analysis of some of the causes
for this gap and strategic directions to help close this
gap. The strategic directions outlined in this
Pharmaceuticals Discussion Paper complement and reinforce
the objectives outlined in the WHO Medicines Strategy:
2000-2003 (World Health Organization, Geneva, 2000,
WHO/EDM/2000.1). The WHO strategy describes specific
objectives, expected outcomes, and progress indicators in
the areas of drug policy, access to essential drugs, quality
and safety, and rational use of medicines. Both the World
Bank and the WHO initiatives rest on a fundamental
commitment to work with governments, on governmental
organizations, the private sector, professional bodies, and
other key actors to help strengthen the pharmaceutical
sector and its ability to contribute to improved health
outcomes.. The current burden of disease falling on the two
billion people living on less than one dollar per day
undermines both individual well-being and collective
economic development. Much of this burden of disease can be
reduced by securing the availability, affordability, and
rational use of essential drugs of assured quality. Yet this
aim can not be achieved by governments alone, by individual
multilateral organizations working alone, or by any other
individual organization. It can only be achieved when
committed governments and local organizations are supported
by clear, consistency, and mutually compatible approaches by
agencies such as the World Bank, WHO, UNICEF, others in the
UN family, bilateral donors, and the broader development
community. This discussion paper provides an important
contribution to this process. |
| format |
Publications & Research :: Working Paper |
| author |
Govindaraj, Ramesh Reich, Michael R. Cohen, Jillian C. |
| author_facet |
Govindaraj, Ramesh Reich, Michael R. Cohen, Jillian C. |
| author_sort |
Govindaraj, Ramesh |
| title |
World Bank Pharmaceuticals |
| title_short |
World Bank Pharmaceuticals |
| title_full |
World Bank Pharmaceuticals |
| title_fullStr |
World Bank Pharmaceuticals |
| title_full_unstemmed |
World Bank Pharmaceuticals |
| title_sort |
world bank pharmaceuticals |
| publisher |
World Bank, Washington, DC |
| publishDate |
2013 |
| url |
http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals http://hdl.handle.net/10986/13734 |
| _version_ |
1764424582861684736 |
| spelling |
okr-10986-137342021-04-23T14:03:10Z World Bank Pharmaceuticals Govindaraj, Ramesh Reich, Michael R. Cohen, Jillian C. APPRAISAL REPORTS BIDDING CAPACITY BUILDING CASE STUDY CONTRACEPTIVES CORRUPTION COUNTERFEIT DRUGS DECISION MAKING DELIVERY SYSTEMS DEVELOPED COUNTRIES DEVELOPING COUNTRIES DEVELOPING COUNTRY DEVELOPMENT GOALS DEVELOPMENT INDICATORS DEVELOPMENT NETWORK DEVELOPMENT PARTNERS DEVELOPMENT STUDIES DISTRIBUTION SYSTEMS DRUG FINANCING DRUG INDUSTRY DRUG POLICY DRUG SELECTION ECONOMIC GROWTH ECONOMICS ESSENTIAL DRUGS FINANCIAL SUPPORT FORMAL POLICY HEALTH CARE HEALTH CARE PROVISION HEALTH EXPENDITURES HEALTH NEEDS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH WORKERS HEPATITIS B HOUSEHOLD INCOME HUMAN CAPITAL HUMAN DEVELOPMENT IMPORTED DRUGS IMPROVED HEALTH INCOME COUNTRIES INDIVIDUAL COUNTRIES INSTITUTIONAL ANALYSIS INTERNATIONAL MARKET INTERVENTION LOW-INCOME COUNTRIES MALARIA MANAGEMENT MANAGEMENT CAPACITY MANAGERS MARKET FAILURES MARKET INCENTIVES MEDICAL SUPPLIES MEDICINE MEDICINES MOTIVATION NATIONAL DRUG POLICIES NATIONAL DRUG POLICY NATIONAL ESSENTIAL DRUG LISTS NATIONAL ESSENTIAL DRUGS LISTS NATIONAL POLICIES NDP NON- GOVERNMENTAL ORGANIZATIONS NUTRITION PARTNER INSTITUTIONS PARTNERSHIP PATENTS PATIENTS PHARMACEUTICAL COMPANIES PHARMACEUTICAL FINANCING PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MARKETING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICIES PHARMACEUTICAL POLICY PHARMACEUTICAL PRICING PHARMACEUTICAL PROCUREMENT PHARMACEUTICAL PRODUCTION PHARMACEUTICAL PRODUCTS PHARMACEUTICAL REFORM PHARMACEUTICAL REGULATORY AGENCIES PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICAL SYSTEMS PHARMACEUTICAL WAREHOUSING PHARMACEUTICALS PHARMACIES POLICY ANALYSIS POLICY DIALOGUE POLICY DOCUMENT POLICY FRAMEWORK POLICY IMPLICATIONS POLICY PROCESS PRICE COMPARISONS PRIMARY HEALTH CARE PRIVATE SECTOR PRIVATE SECTORS PROJECT IMPLEMENTATION PUBLIC AGENCIES PUBLIC HEALTH PUBLIC POLICIES PUBLIC POLICY PUBLIC SECTOR PURCHASING QUALITY ASSURANCE QUALITY CONTROL RATIONAL USE OF DRUGS SAFETY SCHOOLS SOCIAL MARKETING STRUCTURAL ADJUSTMENT TASK TEAM LEADERS TECHNICAL ASSISTANCE THERAPIES VACCINES WIDESPREAD CORRUPTION WORKERS PHARMACEUTICALS BURDEN OF DISEASE HEALTH CARE SYSTEMS MULTILATERAL ORGANIZATIONS HEALTH CARE HEALTH CARE FINANCE HEALTH CARE FINANCING HEALTH SYSTEMS DEVELOPMENT & REFORM Pharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and the reality that for millions of people -- particularly poor and disadvantaged people -- medicines are unavailable, unaffordable, unsafe or improperly used. This World Bank Pharmaceuticals Discussion Paper provides a pragmatic analysis of some of the causes for this gap and strategic directions to help close this gap. The strategic directions outlined in this Pharmaceuticals Discussion Paper complement and reinforce the objectives outlined in the WHO Medicines Strategy: 2000-2003 (World Health Organization, Geneva, 2000, WHO/EDM/2000.1). The WHO strategy describes specific objectives, expected outcomes, and progress indicators in the areas of drug policy, access to essential drugs, quality and safety, and rational use of medicines. Both the World Bank and the WHO initiatives rest on a fundamental commitment to work with governments, on governmental organizations, the private sector, professional bodies, and other key actors to help strengthen the pharmaceutical sector and its ability to contribute to improved health outcomes.. The current burden of disease falling on the two billion people living on less than one dollar per day undermines both individual well-being and collective economic development. Much of this burden of disease can be reduced by securing the availability, affordability, and rational use of essential drugs of assured quality. Yet this aim can not be achieved by governments alone, by individual multilateral organizations working alone, or by any other individual organization. It can only be achieved when committed governments and local organizations are supported by clear, consistency, and mutually compatible approaches by agencies such as the World Bank, WHO, UNICEF, others in the UN family, bilateral donors, and the broader development community. This discussion paper provides an important contribution to this process. 2013-06-04T19:31:08Z 2013-06-04T19:31:08Z 2000-09 http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals http://hdl.handle.net/10986/13734 English en_US HNP discussion paper series; CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo/ World Bank World Bank, Washington, DC Publications & Research :: Working Paper Publications & Research |